Medhi Lahmar, MD, PhD

Boehringer Ingelheim International GmbH
Ingelheim am Rhein, Rheinland-Pfalz, Germany

Disclosure information not submitted.

Presentation(s):

• Paper 43 - BRIGIMADLIN VERSUS STANDARD-OF-CARE DOXORUBICIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS): BRIGHTLINE-1

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST